Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
23 avr. 2024 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $370 - $390 million ––...
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
16 avr. 2024 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at...
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
02 avr. 2024 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– Abiprubart Phase 2b trial in Sjogren’s Disease planned to initiate in 2H 2024 –– Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity –– Abiprubart development...
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
28 févr. 2024 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively – – ARCALYST 2024 net product revenue expected to be $360 - $380 million,...
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
21 févr. 2024 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, February 28, 2024...
Kiniksa Pharmaceuticals Provides Corporate Update
04 janv. 2024 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) – – ARCALYST 2024 net product revenue expected to be $360 - $380 million – – Abiprubart...
Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday,...
Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution
31 oct. 2023 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth – – KPL-404 Phase 2 rheumatoid arthritis data from Cohorts 1-3 now expected in...
Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023
24 oct. 2023 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 31, 2023 at...
Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
25 juil. 2023 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q2 2023 net product revenue of $54.5 million –– ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the...